EXOSC5

Across TCGA pan-cancer cohorts, EXOSC5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXOSC5 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EXOSC5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EXOSC5 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where EXOSC5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.758	0.955	.004	18	view →
HNSC	OS	Quartile	All	0.582	0.897	.004	9	view →
LSCC	OS	Quartile	II,III,IV	0.927	0.575	.026	5	view →
OV	DFS	Median	All	0.871	1.000	.038	4	view →
LUAD	OS	Quartile	All	0.662	1.000	.016	3	view →
GBM	DFS	Quartile	All	0.239	0.442	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXOSC5–PDAC (OS)

Open the PDAC breakdown →